Search Results for: Cybin

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company”

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit”

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs”

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference”